Contributed Poster Presentations Session 2

INFECTIOUS DISEASES AND HIV RESEARCH
PHV1	UTILIZATION OF INTENSIVE CARE AND HOSPITAL DAYS AND OUTCOME IN PATIENTS WITH SEVERE SEPSIS: THE SELECT II REGISTRY Formica CA1, Drabinski A12, Kim S12, Williams GR1, 1Health Economics and Reimbursement, Knoll Pharmaceutical Company, Mount Olive, NJ, USA; 2Office of Health Policy and Clinical Outcomes, Thomas Jefferson University Hospital, Philadelphia, PA, USA
PHV2	THE BURDEN OF RESPIRATORY SYNCTIAL VIRUS (RSV) HOSPITALIZATIONS IN THE US Howard TS, Stang PE, Galt Associates, Sterling, VA, USA
PHV3	MODELLING A COST-OF-ILLNESS STUDY TO EVALUATE THE BURDEN OF INFLUENZA IN ITALY Aimola A, Gianfrate F, Health Economics Department, Glaxo Wellcome, Verona, Italy
PHV4	HEALTH CARE UTILIZATION AND COSTS ASSOCIATED WITH FOUR CATEGORIES OF SKIN ULCERS IN NEW MEXICO MEDICAID PATIENTS Kumar RN1, Gupchup GV1, Dodd M1, Iskedjian M2, Einarson TR2, Raisch DW1, 1University of New Mexico, College of Pharmacy, Albuquerque, NM, USA; 2PharmIdeas Research and Consulting Inc., Hamilton, ON, Canada
PHV5	EFFECTIVENESS AND COSTS OF ANTIBIOTICS IN THE AMBULATORY TREATMENT OF RESPIRATORY TRACT INFECTIONS Laurier C1, Lachaine J1, Manzi P2, 1Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada; 2Abbott Laboratories Ltd., Montreal, QC, Canada
PHV6	ECONOMIC EVALUATION OF A SAFETY DEVICE FOR SUBCUTANEOUS INJECTIONS OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) Durand-Zaleski I1, Gabriel S2, Dinet J2, 1Hôpital Henri-Mondor, Creteil, France; 2Health Economics Department, Sanofi-Synthelabo, Bagneux, France
PHV7	MANAGING PNEUMOCYSTOSIS: THE COST OF HOSPITALIZATION IN THE U.S. O'Brien J, Pierce D, Caro J, Caro Research, Concord, MA, USA
PHV7	UNCOMPLICATED ACUTE PYELONEPHRITIS IN ADULT WOMEN: INPATIENT VERSUS OUTPATIENT THERAPY - ECONOMIC COMPARISON Tibi-Lévy Y1, Elkharrat D2, de Pouvourville G1, for the Group PNA, 1Groupe-IMAGE, ENSP, Saint-Maurice, France; 2SAU, Lariboisière Hospital, Paris, France
PHV8	COST OF TREATING HISPANIC PATIENTS WITH AIDS IN US HOSPITALS O'Brien J, Pierce D, Jackson-Kelley H, Caro J, Caro Research, Concord, MA, USA
PHV19	A PRELIMINARY STUDY: THE PHARMACOECONOMIC PROFILE OF ANTIBIOTIC USE IN TURKEY Sapci H1, Bozkurt E2, Durlu T2, Kandilci B2, Ozsogut B2, Demirdamar R2, 1Numune Hospital, Ankara, Turkey; 2Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
PHV11	COST-MINIMIZATION ANALYSIS OF AZITHROMYCIN IV/PO VERSUS CEFUROXIME IV/PO ± ERYTHROMYCIN IV/PO FOR COMMUNITY-ACQUIRED PNEUMONIA Wong AH12, Phillips E2, Tailor SAN2, Cornish W2, Shear NH12, Lavoie F3, 1HOPE Research Centre, Toronto, ON, Canada; 2Sunnybrook and Women's College Health Sciences Centre, Toronto, ON, Canada; 3Pfizer Canada Inc., Kirkland, QC, Canada
PHV12	MANAGEMENT STRATEGIES FOR RIBAVIRIN-INDUCED HEMOLYTIC ANEMIA IN THE TREATMENT OF HEPATITS C: CLINICAL AND ECONOMIC IMPLICATIONS Devine EB1, Kowdley KV2, Sullivan SD1, Veenstra DL1; 1Department of Pharmacy, University of Washington, Seattle, WA, USA; 2Division of Gastroenterology/Hepatology, University of Washington, Seattle, WA, USA
PHV13	COST ANALYSIS OF CEFTRIAXONE VERSUS CEFTRIAXONE PLUS MACROLIDE TREATMENT FOR PATIENTS HOSPITALIZED WITH COMMUNITY-ACQUIRED PNEUMONIA (CAP) Truong K, Kucukarslan S, Ailani R, Wright D, DiGiovine B, Henry Ford Hospital, Detroit, MI, USA
PHV14	A MULTINATIONAL PHARMACOECONOMIC EVALUATION OF THE SEVEN-VALENT PNEUMOCOCCAL CONJUGATE VACCINE Arikian S1, Ciuryla V2, Doyle JJ13, Casciano J1, Casciano R1, Hvidsten K1, 1The Analytica Group Ltd., New York, NY, USA; 2Wyeth-Ayerst Laboratories, St. Davids, PA, USA; 3Columbia University, School of Public Health, New York, NY, USA
PHV15	CLINICAL AND ECONOMIC BENEFITS OF THE PNEUMOCOCCAL CONJUGATE VACCINE IN CHILDREN Oster G1, Weycker D1, Ciuryla V2, Richardson E1, Thompson D1, 1Policy Analysis Inc. (PAI), Brookline, MA, USA; 2Wyeth-Ayerst Pharmaceuticals, St. Davids, PA, USA
PHV16	AN UNUSUAL ECONOMIC EVALUATION OF EFAVIRENZ COMPARED TO INDINAVIR Migliaccio-Walle K, Raggio G, O'Brien J, Caro J, Caro Research, Concord, MA, USA
PHV17	PRELIMINARY ASSESSMENT OF THE ECONOMIC VALUE OF ADULT PERTUSSIS BOOSTER VACCINATION Botteman MF1, Pashos CL2, Staginnus U3, 1Abt Associates Clinical Trials, Bethesda, MD, USA; 2Abt Associates Clinical Trials, Cambridge, MA, USA; 3SmithKline Beecham Biologicals, Rixensart, Belgium
PHV18	SAFETY-NET HOSPITAL PERSPECTIVE: COST-EFFECTIVENESS OF TREATMENT FOR HEPATITIS C Singer ME, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
PHV19	IMPACT OF ANTIBIOTIC CHOICE ON COSTS, OUTPATIENT VISITS, AND 28-DAY OUTCOMES FOR COMMUNITY-ACQUIRED PNEUMONIA PATIENTS Bell TJ1, Mauskopf JA1, Gallagher KM2, L’Italien GJ2, Anton S2, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Bristol-Myers Squibb, Wallingford, CT, USA
PHV20	COST-EFFECTIVENESS ANALYSIS OF LAMIVUDINE TREATMENT IN CHRONIC HEPATITIS B Yeh YC1, Biddle AK2, Hartzema AG3, 1School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA; 2School of Public Health, University of North Carolina, Chapel Hill, NC, USA; 3Center for Pharmaceutical Outcome Research, University of North Carolina, Chapel Hill, NC, USA
PHV21	PRELIMINARY ASSESSMENT OF THE ECONOMIC VALUE OF PERTUSSIS BOOSTER VACCINATION OF HOSPITAL STAFF Botteman MF1, Pashos CL2, Staginnus U3, 1Abt Associates Clinical Trials, Bethesda, MD, USA; 2Abt Associates Clinical Trials, Cambridge, MA, USA; 3SmithKline Beecham Biologicals, Rixensart, Belgium
PHV22	UTILIZATION AND COST-EFFECTIVENESS OF ANTIMICROBIALS IN COMMUNITY-ACQUIRED PNEUMONIA Karpov O, Zaytsev A, Institute of Pharmacology, Saint-Petersburg, Russia
PHV23	PATIENT ADHERENCE WITH MULTI-DRUG HIV THERAPY: VARIATIONS IN ADHERENCE AND CORRELATION WITH HIV RNA LEVELS Farmer KC1, Rathbun C1, Clay P2, Stephens J1, Bui T1, Slater L1, 1The University of Oklahoma, Health Sciences Center, Oklahoma City, OK, USA; 2University of Missouri, Kansas City, MO, USA
PHV24	DISCRIMINATIVE ABILITY OF THE SF-12 IN A SAMPLE OF PERSONS WITH HIV Delate T, Coons SJ, College of Pharmacy, The University of Arizona, Tucson, AZ, USA
PHV25	QUALITY OF LIFE OF ADULT PATIENTS TREATED FOR A RESPIRATORY TRACT INFECTION Lachaine J1, Laurier C1, Manzi P2, 1Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada; 2Abbott Laboratories Ltd., Montreal, QC, Canada
PHV26	EFFECTIVENESS OF ANTIBIOTIC PRESCRIBING AND PATIENT OUTCOMES IN A COMMUNITY SETTING; THE AUSTRALIAN EXPERIENCE Beilby J1, Marley J1, Walker D1, Chamberlain N1, Lydick E2, Hess G34, Ratcliffe M2, Burke M2, 1University of Adelaide, Adelaide, Australia; 2SmithKline Beecham, Philadelphia, PA, USA; 3Care Management Science, Philadelphia, PA, USA; 4Emory University, Atlanta, GA, USA
PHV27	COSTS AND OUTCOMES OF TREATING FEBRILE NEUTROPENIA IN NINE EUROPEAN COUNTRIES Flynn J1, Elixhauser A3, Constenla D1, Baleva J2, Ciuryla V2, 1MEDTAP International, Bethesda, MD, USA; 2Wyeth-Ayerst, St. Davids, PA, USA; 3Agency for Healthcare Research and Quality, Rockville, MD, USA
PHV28	RETROSPECTIVE ANALYSIS OF INPATIENT COSTS FOR ACUTE PANCREATITIS IN THE UNITED STATES Bell CF, Stephens JM, Dever MT, Semroc GS, PAREXEL International, Outcomes Research Group, Alexandria, VA, USA
PHV29	VARIABILITY IN THE CRITERIA FOR EARLY SWITCH AND EARLY DISCHARGE IN COMMUNITY-ACQUIRED PNEUMONIA: A SYSTEMATIC REVIEW OF THE LITERATURE Rhew DC12, Tu GS1, Ofman J1, Henning JM3, Richards MS3, Weingarten SR1, 1Zynx Health Inc., Cedars-Sinai, Departments of Medicine and Health Services Research, Beverly Hills, CA, USA; 2West Los Angeles VA Medical Center, Los Angeles, CA, USA; 3TAP Holdings Inc., Deerfield, IL, USA
PHV30	COSTS AND OUTCOMES OF A RESPIRATORY SYNCYTIAL VIRUS PROPHYLAXIS PROGRAM IN A MEDICAID MANAGED CARE ORGANIZATION Schaffer M, Amaya MA, Vojta D, Health Partners, Philadelphia, PA, USA
PHV31	FACTORS AFFECTING PHYSICIANS' DECISION MAKING TO DISCHARGE PATIENTS FROM THE HOSPITAL SETTING: A CASE STUDY OF PATIENTS WITH METHICILLIN RESISTANT STAPHYLCOCCUS AUREUS (MRSA) INFECTIONS Yaldo AZ1, Li Z2, Sullivan JL2, Mozaffari E2, 1Pharmacy Health Care Administration, University of Florida, College of Pharmacy, Gainesville, FL, USA; 2Pharmacia and Upjohn, Peapack, NJ, USA
CANCER RESEARCH
PNC1	OUTCOMES AND COSTS OF ACUTE MYELOID LEUKEMIA OVER ONE YEAR FOLLOWING DIAGNOSIS: AN ANALYSIS OF SEER-MEDICARE DATA Menzin J1, Lang K1, Earle CE2, Kerney D1, 1Boston Health Economics, Inc., Billerica, MA, USA; 2Harvard Medical School, Boston, MA, USA
PNC2	COSTS OF PALLIATIVE CHEMOTHERAPY OF ADVANCED COLORECTAL CANCER - A COMPARISON OF TWO PRESENT TREATMENT SCHEMES Kilburg A2, Grothey A1, Pfeil T2, Siedentop H2, Sacha M2, Rychlik R2, 1Martin Luther University, Halle Wittenberg, Germany; 2Institute of Empirical Health Economics, Burscheid, Germany
PNC3	PREDICTORS OF CERVICAL CANCER INPATIENT ADMISSION COSTS BY STAGE Berg GD, Chattopadhyay SK, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA
PNC4	APPLICATION OF PHARMACOECONOMICS AND OUTCOMES RESEARCH ON DECISION-MAKING PATTERNS BY MEDICAL ONCOLOGISTS Sarpong DF, Jamero DJ and Ball CK, Xavier University, College of Pharmacy, New Orleans, LA, USA
PNC5	COST-EFFECTIVENESS OF EARLY DETECTION AND PREVENTION OF COLORECTAL CANCER BY SCREENING WITH FECAL OCCULT BLOOD TESTS Parson RE, Baker JT, Beckman Coulter, Inc., Primary Care Diagnostics, Palo Alto, CA, USA
PNC6	COST-EFFECTIVENESS OF GENETIC TESTING IN HEREDITARY NON-POLYPOSIS COLORECTAL CANCER Henderson LB12, Scheuner MT1, Ofman JJ12, 1Cedars Sinai Medical Center, Los Angeles, CA, USA; 2Zynx Health, Inc., Beverly Hills, CA, USA
PNC7	COST-EFFECTIVENESS OF RITUXIMAB IN RELAPSED, REFRACTORY, LOW-GRADE NON-HODGKIN'S LYMPHOMA Cattaneo MJ, Nichol MB, Department of Pharmaceutical Economics and Policy, University of Southern California, School of Pharmacy, Los Angeles, CA, USA
PNC8	PHARMACOECONOMICS OF COMBINATION OF CHEMOTHERAPY WITH DOCETAXEL IN ADVANCED BREAST CANCER Poddubnaya IV1, Arkadyeva TV2, Kobina SA3, 1Cancer Research Center of Russia, Moscow, Russia; 2City Oncology Hospital, Krasnodar, Russia; 3Aventis Pharmaceuticals, Moscow, Russia
PNC9	PATTERNS OF EPOETIN ALPHA UTILIZATION IN ANEMIC CANCER PATIENTS Scott WG1, Arbuckle RB2, McCormick W1, Sansgiry SS1, 1University of Houston, College of Pharmacy, Houston, TX, USA; 2The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
PNC10	PSYCHOMETRIC VALIDITY OF QUALITY OF LIFE AND UTILITY MEASURES IN NON-SMALL CELL LUNG CANCER (NSCLC): A LITERATURE REVIEW Emery MP1, Adesina K1, Marquis P2, Van Gool R3, 1Mapi Research Institute, Lyon, France; 2Mapi Values, Lyon, France; 3Janssen Research Foundation, Beerse, Belgium
PNC11	SYMPTOMATIC ANEMIA DURING CANCER CHEMOTHERAPY: rhERYTHROPIETIN (rhEPO) AND QUALITY OF LIFE Bonicatto S, Giacomi N, Ferreras R, De la Cruz J, Cichetti G, Gelemur M, Riva M, Ivulich C, Ferreyra L, Fundación FUNDONAR, la Plata, Bosas, Argentina
PNC12	RACIAL DIFFERENCES IN THE COST OF TREATING EARLY STAGE PROSTATE CANCER Brandeis J1, Pashos CL3, Henning JM2, Litwin MS1, 1Departments of Urology and Health Services, University of California, Los Angeles, CA, USA; 2TAP Holdings, Deerfield, IL, USA; 3Abt Associates Clinical Trials, Cambridge, MA, USA
PNC13	COLONOSCOPY CHARGES IN A MANAGED CARE POPULATION: DIFFERENCES BASED ON POLYPECTOMY AND MALIGNANCY STATUS Gandhi SK1, Mehta SS1, McLaughlin T2, Okamoto L2, Boyer JG1, 1Searle, Skokie, IL, USA; 2NDC Health Information Services, Phoenix, AZ, USA
PNC14	EFFECTIVENESS OF ERYTHROPOIETIN IN CANCER PATIENTS Morris C, Halberg DL, McIntyre WJ, University of Arkansas for Medical Sciences, Little Rock, AR, USA
PNC15	COST-EFFECTIVENESS OF TAMOXIFEN IN BREAST CANCER RISK REDUCTION Sengupta N, Hay JW, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA, USA
PNC16	VALIDITY OF THE TIME-TRADE OFF TECHNIQUE IN DETERMINING PREFERENCES FOR THE TREATMENT OF PROSTATE CANCER Watkins Bruner D, Baron J, Fox Chase Cancer Center, Cheltenham, PA, USA
PNC17	CONVENIENCE IS THE MAIN REASON WHY OVARIAN CANCER PATIENTS PREFER ORAL REGIMEN Calhoun EA, Roland PY, Northwestern University, Chicago, IL USA
DIABETES RESEARCH
PDB1	RESOURCE USE AND COST ASSOCIATED WITH MICRO- AND MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES Goertz A1, Spannheimer A2, Reitberger U2, Liebl A3, Neiss A4, 1SmithKline Beecham Pharmaceuticals, Munich, Germany; 2Kendle International Inc., Munich, Germany; 3Diabetes Center Bogenhausen, Munich, Germany; 4Institute for Medical Statistics and Epidemiology at the Technical University, Munich, Germany
PDB2	THE EFFECTS OF AGE AND COMPLICATIONS ON THE COST OF MANAGING MEMBERS WITH TYPE 1 DIABETES MELLITUS Martinson MS, Liao E, Newell JA, PharMetrics, Inc., Boston, MA, USA
PDB3	THE EFFECTS OF AGE AND COMPLICATIONS ON THE COST OF MANAGING MEMBERS WITH TYPE 2 DIABETES MELLITUS Martinson MS, Liao E, Newell JA, PharMetrics, Inc., Boston, MA, USA
PDB4	COST EFFECTIVENESS OF DIABETIC FOOT ULCER TREATMENT WITH AUTOLOGOUS PLATELET RELEASATE Kantor J1, Margolis DJ2, Department of Biostatistics and Epidemiology, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA; 2Department of Dermatology, University of Pennsylvania, School of Medicine, Philadelphia, PA, USA
PDB5	COST-EFFECTIVENESS OF RENTINOPATHY SCREENING IN PEDIATRIC PATIENTS WITH TYPE I DIABETES MELLITUS Li J, Hay J, Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
PDB6	EVALUATION OF CLINICAL AND DEMOGRAPHIC FACTORS ASSOCIATED WITH DIABETIC FOOT ULCER TREATMENT COSTS Wade SW1, Kadlubek PJ1, Fastenau JM2, Gause D2, Thomasson J1, Goldberg GA1, 1Protocare Sciences, Inc., Santa Monica, CA, USA; 2Novartis Pharmaceuticals Corp, East Hanover, NJ, USA
PDB7	TREATMENT COSTS OF TYPE-2 DIABETES MELLITUS PATIENTS WITH AND WITHOUT SELECTED CARDIOVASCULAR COMORBIDITIES Bhattacharyya SK1, Else BA2, 1Procter & Gamble Pharmaceuticals, Mason, OH, USA; 2Merck-Medco Managed Care, LLC, Franklin Lakes, NJ, USA
PDB8	HEALTH RELATED QUALITY OF LIFE (HRQOL) MEASURES IN TYPE 2 DIABETES Chang J, Guo A, Rodriguez J, Chen Y, McNulty P, Martens L, ICOM Health Economics, Johnson and Johnson, Raritan, NJ, USA
PDB9	COST OF CONCOMITANT ILLNESSES AMONG PATIENTS WITH HYPERTENSION AND DIABETES Farquhar IV1, Jackson JD1, Weir E2, 1Bristol-Myers Squibb Company, Princeton, NJ, USA; 2Analytical Computing, Baltimore, MD, USA
PDB10	ECONOMIC OUTCOMES OF HMG CoA REDUCTASE INHIBITORS IN A HYPERTENSIVE DIABETIC POPULATION IN A MANAGED CARE ORGANIZATION White TJ, Juzba M, Berenbeim DM, Gilderman AM, Salas JC, Prescription Solutions: A Subsidiary of PacifiCare Health Plans, Costa Mesa, CA, USA
PDB11	EVALUATION OF A DIABETES DISEASE MANAGEMENT PROGRAM IN A NURSING HOME Longe RL12, Wagner PJ2, 1University of Georgia, Athens, GA, USA; 2Medical College of Georgia, Augusta, GA, USA
RENAL AND URINARY DISORDERS RESEARCH
PRN1	OVERACTIVE BLADDER COST OF ILLNESS: ANALYSIS OF MEDI-CAL CLAIMS Bailey KL1, Torigoe Y2, Zhou S2, Mo LS2, Flewelling SL2, 1Pharmacia & Upjohn, Peapack, NJ, USA; 2Greenstone Healthcare Solutions, Peapack, NJ, USA
PRN2	COST-EFFECTIVENESS OF BASILIXIMAB, DACLIZUMAB, AND OKT3 AS INDUCTION AGENTS IN KIDNEY TRANSPLANTATION Shin GP, Johnson N, Vasquez E, Walton S, University of Illinois at Chicago, College of Pharmacy, Chicago, IL, USA
PRN3	COST ANALYSIS OF "OPTIMAL" US DIALYSIS MODALITY UTILIZATION Just PM1, Mendelssohn DC2, Mehta RL3, 1Baxter Healthcare Corporation, Deerfield, IL, USA; 2University of Toronto, Toronto, ON, Canada; 3University of California at San Diego, San Diego, CA, USA
PRN4	ASSESSING QUALITY OF LIFE IN ROUTINE CLINICAL PRACTICE: A PILOT STUDY IN PATIENTS WITH RENAL DISEASE Wild D1, Grove A1, Keogh A2, Farina C3, 1Oxford Outcomes, Oxford, UK; 2Leicester General Hospital, Leicester, UK; 3Janssen-Cilag Ltd, Saunderton, UK
PRN5	QUALITY OF LIFE AND HEALTH CARE RESOURCE UTILIZATION IN PEOPLE WITH URGE INCONTINENCE Rosner AJ1, Becker DL1, Borrie MJ2, Hobbs C3, Fedorkow DM3, Vallely JF2, King HJ2, Turpie I3, 1Innovus Research Inc., Burlington, ON, Canada; 2University of Western Ontario, London, ON, Canada; 3McMaster University, Hamilton, ON, Canada
PRN6	DEVELOPING A SPECIFIC HRQL INSTRUMENT FOR OVERACTIVE BLADDER Coyne K1, Schmier J1, Hunt T2, Corey R2, Liberman J3, Revicki D1, 1MEDTAP International, Bethesda, MD, USA; 2Pharmacia & Upjohn, Peapack, NJ, USA; 3Innovative Medical Research, Towson, MD, USA
PRN7	RELIABILITY OF REPORTING ON COPING STRATEGIES AND IMPACT OF OVERACTIVE BLADDER Stewart WF1, Hunt T2, Payne CK3, 1Innovative Medical Research, Towson, MD, USA; 2Pharmacia & Upjohn, Peapack, NJ, USA; 3Stanford University Medical Center, CA, USA
PRN8	MEDICAL CARE OF OVERACTIVE BLADDER IN ELDERLY MEDICARE PATIENTS Jensen GA1, Zhou Z2, Torigoe Y2, 1Institute of Gerontology and Department of Economics, Wayne State University, Detroit, MI, USA; 2Greenstone Healthcare Solutions, Inc., Kalamazoo, MI, USA
PRN9	THE INFLUENCE OF PHARMACEUTICAL CARE SERVICES ON THE BLOOD PRESSURE OF RENAL TRANSPLANT PATIENTS Chisholm MA12, Vollenweider LJ1, Martin BC1, Mulloy L2, Jagadeesan M2, DiPiro JT12, 1The University of Georgia, College of Pharmacy, Athens, GA, USA; 2Medical College of Georgia, School of Medicine, Augusta, GA, USA
RESPIRATORY DISORDERS RESEARCH
PRS1	DIRECT AND INDIRECT COSTS OF ASTHMA TO AN EMPLOYER Birnbaum HG1, Greenberg PE1, Wanke LA2, Atkins K2, 1Analysis Group/Economics, Cambridge, MA, USA; 2Immunex Corporation, Seattle, WA, USA
PRS2	IMPACT OF A TARGETED ASTHMA INTERVENTION PROGRAM ON TREATMENT COSTS Suh DC1, Shin SK1, Voytovich RM2, Okpara I1, Zimmerman A2, 1Rutgers-The State University of New Jersey, College of Pharmacy, Piscataway, NJ, USA; 2National Prescription Administrators, Inc., East Hanover, NJ, USA
PRS3	TRENDS IN THE USE OF ß-AGONIST MEDICATIONS IN BRITISH COLUMBIA: AN ANALYSIS OF BC PHARMACARE DATA Lynd LD1, Raboud J12, Guh D2, Paré PD2, Anis AH12, 1Deptarment of Health Care and Epidemiology, University of British Columbia, Vancouver, BC, Canada; 2Centre for Health Evaluation and Outcome Sciences, St. Paul's Hospital, Vancouver, BC, Canada
PRS4	IDENTIFYING PREDICTORS OF THE ASTHMA-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE FOR NATIVE-AMERICAN ADULTS (AQLQ-NAA) Gupchup GV1, Kumar RN1, Tonrey L2, Riley K2, 1University of New Mexico College of Pharmacy, Albuquerque, NM, USA; 2PHS Albuquerque Indian Hospital, Albuquerque, NM, USA
PRS5	IMPACT OF INHALED CORTICOSTEROIDS (FLUTICASONE PROPIONATE) ON ECONOMIC OUTCOMES IN A MANAGED CARE ENVIRONMENT Oates V1, Vaziri B1, Ober J2, Gothard L2, 1Advance Paradigm, Hunt Valley, MD, USA, 2Glaxo Wellcome, Inc., Research Triangle Park, NC, USA
PRS6	CLASSIFYING ASTHMA SEVERITY BASED ON PRESCRIPTION DRUG CLAIMS Leahy MJ1, Klingman D2, Bell CF2, 1Leahy & Associates, LLC, Old Lyme, CT, USA; 2PAREXEL International, Outcomes Research Group, Alexandria, VA, USA
PRS7	DRIVERS OF DIAGNOSIS OF OBSTRUCTIVE LUNG DISEASE, BY STAGE OF SEVERITY Silberman C1, Lally C2, Lydick E1, 1SmithKline Beecham Pharmaceuticals, Collegeville, PA, USA; 2Rollins School of Public Health, Emory University, Atlanta, GA, USA
PRS8	ECONOMIC OUTCOMES OF STEROID INHALER USE PATTERNS IN A MANAGED CARE ORGANIZATION White TJ, Juzba M, Berenbeim DM, Gilderman AM, Salas JC, Prescription Solutions - A subsidiary of PacifiCare Health Plans, Costa Mesa, CA, USA
PRS9	PREDICTORS OF HOSPITALIZATION AND EMERGENCY ROOM USE IN A MEDICAID MANAGED CARE ASTHMATIC POPULATION Drabinski AM1, Schaffer M2, Chatterton ML1, 1Thomas Jefferson University, Philadelphia, PA, USA; 2Health Partners, Philadelphia, PA, USA
PRS10	ANNUAL COST OF TREATING ASTHMA IN A MANAGED CARE POPULATION Yazdani C1, Stanford R2, McLaughlin T1, Margraf T3, 1NDC Health Information Services, Phoenix, AZ, USA; 2Glaxo Wellcome Inc, Research Triangle Park, NC, USA; 3Pharmetrics, Inc., Boston, MA, USA
SURGICAL PROCEDURES AND HOSPITAL RESOURCE USE RESEARCH
PSG1	INPATIENT UTILIZATION OF MEDICAL SERVICES ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE-RELATED INPATIENT PROCEDURES IN THE DEPARTMENT OF DEFENSE Zachry WM, Shepherd MD, Wilson JP, The University of Texas at Austin, Austin, TX, USA
PSG2	TEN-YEAR COSTS ASSOCIATED WITH PERIPHERAL ARTERIAL DISEASE-RELATED INPATIENT PROCEDURES IN THE DEPARTMENT OF DEFENSE Zachry WM, Shepherd MD, Wilson JP, Lawson KA, The University of Texas at Austin, Austin, TX, USA
PSG3	COSTS INCURRED DURING INPATIENT ADMISSION FOR COMMON SURGERIES: PRELIMINARY RESULTS Strassels S1, Chen C2, Carr D1, McDonagh M1, Gouveia W1, Wurm H1, 1New England Medical Center, Boston, MA, USA; 2Searle Pharmaceuticals, Skokie, IL, USA
PSG4	TRAUMATIC COLON INJURIES: DIFFERENCE IN HOSPITAL COSTS BY TYPE OF SURGICAL REPAIR O'Brien J1, Pierce D1, Jacobs L2, 1Caro Research, Concord, MA, USA; 2Department of Traumatology and Emergency Medicine, Hartford Hospital, Hartford, CT, USA
PSG5	THE ECONOMIC IMPACT OF THE USE OF PERFLUORO-N-OCTANE DURING RETINAL DETACHMENT SURGERY Venkataraman KS1, Barnes JR1, Scott IU2, 1Alcon Laboratories, Inc., Ft Worth, TX, USA; 2Bascom Palmer Eye Institute, Miami, FL, USA
PSG6	COST-MINIMIZATION ANALYSIS OF EPOETIN ALPHA IN THE COMMUNITY HOSPITAL Santorello JG, State University of New York at Stony Brook, Stony Brook, NY, USA
PSG7	POSTOPERATIVE PAIN RELIEF, INTERFERENCE WITH ACTIVITIES, AND SATISFACTION: PRELIMINARY RESULTS Strassels S1, Chen C2, Carr D1, McDonagh M1, Gouveia W1, Wurm H1, 1New England Medical Center, Boston, MA, USA; 2Searle Pharmaceuticals, Skokie, IL, USA
PSG8	LONG-TERM OUTCOMES AND RESOURCE USE ASSOCIATED WITH MYOMECTOMY Subramanian S, Clark MA, Quinn VC, Boston Scientific Corporation, Natick, MA, USA
PSG9	CLINICAL AND ECONOMIC OUTCOMES OF CORONARY ANGIOPLASTY ALONE OR IN COMBINATION WITH STENTS IN ACADEMIC HEALTH CENTERS: A RETROSPECTIVE DATABASE ANALYSIS Oinonen MJ1, Akhras KS2, Chen C2, Matuszewski KA1, Vlasses PH3, 1University HealthSystem Consortium, Oak Brook, IL, USA; 2Searle, Skokie, IL, USA; 3American Council on Pharmaceutical Education, Chicago, IL, USA
PSG10	RESTENOSIS AND MEDICAL COSTS FOLLOWING PERCUTANEOUS TRANSLUMINAL CORORNARY ANGIOPLASTY (PTCA) WITH AND WITHOUT STENT Sen S1, Khandker R2, Roth D2, Thomas J1, 1School of Pharmacy, Purdue University, West Lafayette, IN, USA; 2SmithKline Beecham, Collegeville, PA, USA
PSG11	COST ANALYSIS OF INHALED AGENTS IN CANADIAN PEDIATRIC HOSPITALS Bussières JF, Giguère M, Hôpital Sainte-Justine, Montreal, QC, Canada
PSG12	HOSPITAL COST SAVINGS FROM SEVERITY-ADJUSTED LENGTH OF STAY FOLLOWING SURGERY FOR INTRA-ABDOMINAL INFECTION AND TREATMENT WITH PIPERACILILN/TAZOBACTAM OR IMIPENEM/CILASTATIN Bjerke S1, Mallick R2, Clark K2, Wible M2, Zito E2, Guttman R2, Sillup G2, 1Methodist Hospital of Indianapolis, Indianapolis, IN, USA; 2Wyeth-Ayerst Research, Radnor, PA, USA
PSG13	PROPHYLAXIS OF POST-OPERATIVE NAUSEA AND VOMITING: TESTING THE VALUE OF A DOLASETRON-BASED ALGORITHM Darkow T1, Harper ML1, Goulson DT2, 1University of Kentucky, College of Pharmacy, Lexington, KY, USA; 2Department of Anesthesiology, University of Kentucky, Chandler Medical Center, Lexington, KY, USA
PSG14	COST EFFECTIVE STRATEGIES: ASSESSING PHARMACISTS INTERVENTION IN A COMMUNITY HOSPITAL INTENSIVE CARE UNIT Dilanchian P, Sansgiry SS, University of Houston, College of Pharmacy, Houston, TX, USA
GASTROINTESTINAL DISORDERS RESEARCH
PGD1	OVER-THE-COUNTER NSAID USE AND GI TOXICITY Bloom BS1, Straus WL2, Thomas J3, Berger MI2, 1University of Pennsylvania, Philadelphia, PA, USA; 2Purdue University, West Lafayette, IN, USA; 3Merck & Co, West Point, PA, USA
PGD2	IMPROVED DRUG COMPLIANCE USING EDUCATION AFFECTS MEDICAL UTILIZATION AND QUALITY OF LIFE FOR PEPTIC ULCER DISEASE PATIENTS Addiego J1, Berger J1, McStay P1, Craig R2, O'Leary W1, Slezak J1, Schwaab M1, Hasan E1, Apolinski L1, 1Caremark, Northbrook, IL, USA; 2NUMS, Chicago, IL, USA
PGD3	PROSPECTIVE EVALUATION OF AN INFORMATION DISSEMINATION PROGRAM INCORPORATING PEER COMPARISON FEEDBACK IN PEPTIC ULCER DISEASE MANAGEMENT Dennett SL1, Thomas J I2, Sen S2, Bernard PG3, Cramer S4, Schumacher J3, Lang J3, 1Research Triangle Institute, Research Triangle Park, NC, USA; 2Purdue University, West Lafayette, IN, USA; 3Anthem Prescription Management, Inc., Mason, OH, USA; 4Anthem Blue Cross and Blue Shield, Mason, OH, USA
PGD4	THE CLINICAL AND ECONOMIC IMPACT OF COMPETING MANAGEMENT STRATEGIES FOR GASTROESOPHAGEAL REFLUX DISEASE (GERD) Ofman J1, Fennerty MB2, Dorn G1, Fass R3, 1Zynx Health Inc., Cedars-Sinai Departments of Medicine and Health Services Research, Beverly Hills, CA, USA; 2Oregon Health Sciences University, Portland, OR, USA; 3Tuscon VA Medical Center, Tucson, AZ, USA
DRUG USE AND DRUG / HEALTHCARE POLICY RESEARCH
PDH1	ECONOMIC IMPLICATIONS FOR SAFETY-NET HOSPITALS: SCREENING FOR HEPATITIS C Singer ME, School of Medicine, Case Western Reserve University, Cleveland, OH, USA
PDH2	FACTORS RELATED TO PRESCRIPTION DRUG EXPENDITURE GROWTH: VOLUME VS. PRICE Chawla AJ1, Dubois RW2, Neslusan CA1, Smith MS1, Wade SW2, 1The MEDSTAT Group, Inc., Washington, DC, USA; 2Protocare Sciences, Santa Monica, CA, USA
PDH3	PHARMACEUTICAL PRICE CONTROLS AND POSITIVE DRUG LIST EFFECTS ON TOTAL AND SOCIAL INSURANCE EXPENDITURES Karokis A1, Christodoulopoulou A1, Tsiaras T1, Mossialos E2, 1Health Economics and Business Development, AstraZeneca S.A., Athens, Greece; 2LSE Health, London, UK
PDH4	TECHNOLOGY ASSESSMENT IN THE US: WHAT DO PAYERS UNDERSTAND AND WHAT INFORMATION DO THEY WANT? Evans C1, Crawford B1, Dukes E2, 1MAPI Values, Boston, MA, USA; 2Purdue Pharma LP, Norwalk, CT, USA
PDH5	HEALTH CARE EXPENDITURE IN AN HMO BEFORE AND AFTER AN EXCLUSIVE PHARMACY PARTNERSHIP Peris A, Castiglione B, Vanscoy GJ, Stadtlander Operating Co., Pittsburgh, PA, USA
PDH6	ADVANTAGES AND LIMITS OF THE FRENCH HOSPITAL DATABASE (PMSI) ON DESCRIPTION OF HAEMOPHILIA MANAGEMENT AND COSTS Jasso-Mosqueda JG1, Omnes LF1, Gomez E2, Losa N2, Chicoye A1, Durand-Zaleski I3, 1ACE, Neuilly sur Seine, France; 2Mission PMSI Ministère de la Santé, Paris, France; 3Unité Evaluation Etudes, Hôpital Henry Mondor, Créteil, France
PDH7	THE IMPACT OF LOCUS OF CONTROL ON COMPLIANCE Reed P1, Gourley G1, Herrier R2, Gourley D1, 1University of Tennessee, Memphis, TN, USA; 2University of Arizona, Tucson, AZ, USA
PDH8	SUBSPECIALISTS: DO THEY PROVIDE BETTER QUALITY AND MORE EFFICIENT CARE? AN ANALYSIS OF OUTCOMES DATA FROM 6 HOSPITALS Weingarten SR1, Lloyd LE2, Braunstein GD1, 1Cedars-Sinai Health System, Los Angeles, CA, USA; 2Cleveland Health Quality Choice, Cleveland, OH, USA
PDH9	DRUG AND EXAMINITION IN RELATION TO THE TOTAL THERAPY COSTS - A COST MANAGEMENT DILEMMA? Schmelzer A1, Klask J2, L&3246;sch M3, 1Department of ORL, Ruhr University, Bochum, Germany; 2Department of ORL, ENT Clinic University, Essen, Germany; 3Department of Economics and Business Administration, Ruhr University, Bochum, Germany
PDH10	POTENTIAL VALUE FOR MONEY OF RESEARCH: BETA INTERFERON AND THE UK-MS STUDY Davies L, Smith D, Centre for Health Economics, University of York, York, UK
PDH11	EVALUATION OF CIGARETTE SMOKERS' PERCEPTIONS OF SMOKING CESSATION AND THE ROLE OF HEALTH CARE PROFESSIONALS Dodd MA, Gupchup GV, New Mexico Medicaid Retrospective Drug Utilization Review Program, College of Pharmacy, The University of New Mexico, Albuquerque, NM, USA
PDH12	A RANDOMIZED CONTROLLED MULTI-CENTER STUDY EVALUATING THE EFFECT OF PHARMACEUTICAL CARE ON CHANGES IN QUALITY OF LIFE Malone DC1, Carter BL2, Billups SJ3, Ellis S2, 1Univeristy of Arizona, College of Pharmacy, Tucson, AZ, USA; 2University of Colorado, School of Pharmacy, Denver, CO, USA; 3Kaiser Permanente, Denver, CO, USA
PDH13	QUALITY OF CARE INFERENCES FROM MULTIVARIATE ANALYSIS OF AMBULATORY DATA Kroch E123, Brailer D23, 1Villanova University, Villanova, PA, USA; 2Care Management Science, Philadelphia, PA, USA, 3University of Pennsylvania, Philadelphia, PA, USA
PDH14	COMPLIANCE AND PERSISTENCY BENEFITS ACHIEVED BY UTILIZING A ONCE DAILY EXTENDED RELEASE MEDICATION VS A TWICE DAILY REGIMEN Dezii CM, Kawabata H, Tran M, Bristol-Myers Squibb, Managed Health Care Economics and Outcomes Group, Plainsboro, NJ, USA
PDH15	USE OF STANDARD VOCABULARIES AND METRICS FOR COMPARABLE OUTCOMES AND UTILIZATION DATA Scherpbier HJ, Ariosto DJ, Casey SH, Care Management Science Corporation, Philadelphia, PA, USA
PDH16	IDENTIFYING PATIENTS WITH PSYCHOSES IN A MEDICAID MANAGED CARE ORGANIZATION WITH CARVED-OUT BEHAVIORAL HEALTH SERVICES Bachleda MJ1, Moxey E1, Goldfarb N1, Schaffer M2, 1Office of Health Policy and Clinical Outcomes, Thomas Jefferson University, Philadelphia, PA, USA; 2Health Partners, Philadelphia, PA, USA
PDH17	ARE THE BRITISH GOVERNMENT'S HEALTHCARE REFORMS TARGETTING PATIENTS' NEEDS? EVIDENCE FROM A COMPARISON OF TWO GP SURVEYS ON MUSCULOSKELETAL CARE Dickson DJ1, Hosie G1, English J2, Dickson AJ1, 1PCR Society, Northallerton, N. Yorks, UK; 2Wokingham, Berks, UK
PDH18	ENTER THE DRAGON: PHARMACOECONOMICS IN ASIA Pang F1, Tran G2, 1University of York, York, UK; 2The Lewin Group, Bracknell, UK
PDH19	ANALYSIS OF THE TOTAL COST AND RESOURCES CONSUMED IN CASES OF SINGLE AND CONCURRENT CHRONIC ILLNESS Garis RI1, Farmer KC2, Jacobs EW2, 1Department of Pharmaceutical and Administrative Sciences, Creighton University, Omaha, NE, USA, 2Department of Pharmacy Administration, University of Oklahoma, Oklahoma City, OK, USA
PDH20	CONTENT ANALYSIS OF PHARMACOECONOMIC ADVERTISING IN SPECIALTY AND PRIMARY CARE JOURNALS Sullivan PW1, Hirsch JD2, Nichol MB1, Conner C2, Teratanaut R2, 1University of Southern California, Los Angeles, CA, USA; 2Allergan, Inc., Irvine, CA, USA
PDH21	PRE-POST AND BETWEEN GROUP DIFFERENCES IN PATIENT OUTCOMES IN A PHARMACEUTICAL CARE INTERVENTION PROJECT Kamath TV, Chaikledkaew U, Johnson KA, Department of Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, CA, USA
PDH22	MODELLING THE BENEFITS OF VERTEPORFIN THERAPY IN MACULAR DEGENERATION Smith D13, Fenn P2, Drummond M1, 1Centre for Health Economics, University of York, York, UK; 2The Business School, University of Nottingham, Nottingham, UK; 3The University of Washington, School of Pharmacy, Seattle, WA, USA
PDH23	RELEVANCE OF PHARMACOECONOMICS AND HEALTH OUTCOMES INFORMATION TO HEALTH CARE DECISION MAKERS IN THE UNITED STATES Cox E, Motheral B, Griffis D, The University of Arizona, College of Pharmacy, Tucson, AZ, USA
PDH24	PHARMACEUTICAL INDUSTRY PERCEPTIONS OF THE USE OF PHARMACOECONOMIC DATA BY HEALTH CARE ORGANIZATIONS Armstrong EP, Abarca J, Motheral BR, Grizzle AJ, College of Pharmacy, The University of Arizona, Tucson, AZ, USA
PDH25	A QUALITATIVE ASSESSMENT OF MANAGED CARE DECISION-MAKERS' VIEWS AND USE OF PHARMACOECONOMIC INFORMATION Grizzle A, Motheral B, Garrity B, Cox E, Armstrong E, University of Arizona, College of Pharmacy, Tucson, AZ, USA
PDH26	A NATIONAL SURVEY OF DECISION-MAKERS IN MANAGED CARE ON THEIR VIEWS AND USE OF PHARMACOECONOMIC INFORMATION Motheral B, Grizzle A, Armstrong E, Cox E, Bataoel J, Bennett D, Shahriar J, University of Arizona College of Pharmacy, Tucson, AZ, USA
PDH27	THE SATISFACTION AND ECONOMIC EVALUATION OF CONVERTING A TRADITIONAL HOSPITAL SYSTEM USING A UNIT DOSE SYSTEM, AT A HOSPITAL IN BARBADOS, WEST INDIES Griffith JA, Lai L, NOVA Southeastern University, Fort Lauderdale, FL, USA
PDH28	A DRUG COST MODEL FOR A CAPITATED PATIENT POPULATION WITHIN AN INTEGRATED HEALTH CARE SYSTEM Patel RP, Petitta A, Andrews MJ, Henry Ford Health System, Bingham Farms, MI, USA
PDH29	FACTORS AFFECTING ASTHMATIC, DIABETIC, AND HYPERTENSIVE PATIENT SELF-REPORTED COMPLIANCE IN A PHARMACEUTICAL CARE DEMONSTRATION PROJECT Chaikledkaew U, Kamath T, Johnson KA, Department of Pharmaceutical Economics and Policy, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
PDH30	ROLE OF HRQL EVALUATION IN THE DRUG REGULATORY PROCESS: PRELIMINARY RESULTS FROM A EUROPEAN REGULATORY SURVEY Acquadro C, Mapi Research Institute, Lyon, France, for the European Regulatory Issues on QoL Assessment (ERIQA) Group
PDH31	HEALTH RELATED QUALITY OF LIFE AND REGULATORY ISSUES: COMPARISON OF US AND EUROPEAN INITIATIVES Marquis P1, Abetz L2, Acquadro C3, for the ERIQA Group, 1Mapi Values, Lyon, France; 2Mapi Values, Bollington, UK; 3Mapi Research Institute, Lyon, France
PDH32	COST IMPACT OF A PRESCRIPTION BENEFIT CHANGE IN A MEDICARE MANAGED CARE PLAN Balkrishnan R1, Byerly WG2, 1Wake Forest University, School of Medicine, Winston-Salem, NC, USA; 2Wake Forest University, Baptist Medical Center, Winston-Salem, NC, USA
PDH33	EVALUATION AND TREATMENT OF SHORT STATURE: NATIONAL COOPERATIVE GROWTH STUDY (NCGS) EXPERIENCE Blethen SL, Genentech, Inc., South San Francisco, CA, USA